

30 April 2024

**Privatisation by way of scheme of arrangement**

**Disclosure of dealings in the shares of SciClone Pharmaceuticals (Holdings) Limited**

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

| <b>Party</b>                 | <b>Date</b>   | <b>Purchase / Sale</b> | <b>Number of shares</b> | <b>Price per share</b> | <b>Resultant balance (including those of any person with whom there is an agreement or understanding)</b> | <b>Percentage of class (including those of any person with whom there is an agreement or understanding)</b> |
|------------------------------|---------------|------------------------|-------------------------|------------------------|---|---|
| SCLN ESOP Management Limited | 29 April 2024 | Sale                   | 1,020,350               | \$0.0000               | 3,384,023   | 0.5382%   |

End

Note:

SCLN ESOP Management Limited is a party acting in concert with the Offeror.

Dealings were made for its own account.



SCLN ESOP Management Limited is wholly owned by Maples Trustee Services (Cayman) Limited acting solely in its capacity as trustee of the SciClone Trust (being the employee share trust established pursuant to the terms of the option incentive plan approved and adopted by the Company on 24 June 2018 (“**Option Incentive Plan**”) and the post-IPO Restricted Share Unit Plan of the Company adopted by shareholders’ resolution on 22 January 2021 (“**Post-IPO RSU Plan**”)).

1,020,350 Shares were transferred by SCLN ESOP Management Limited in satisfaction of the vesting of share awards pursuant to the Post-IPO RSU Plan.